Bei Akademie registrieren
Johnson & Johnson, US4781601046

Johnson & Johnson stock at EUR 254.73, up 1.75% premarket

Published on 11/12/2026 at 07:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson develops medicines, medical devices and consumer health products. The reference base is the Xetra close of November 11, 2026 at EUR 250.35.

Healthcare portfolio sets context

  • Johnson & Johnson operates through its Innovative Medicine and MedTech segments.
  • Innovative Medicine covers areas including immunology, infectious diseases, neuroscience and oncology.
  • MedTech includes products for interventional solutions, orthopaedics, surgery and vision.
Johnson & Johnson, US4781601046, Illustration mit AI erstellt.
Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson stock traded at 254.73 euros on Lang & Schwarz at 07:52 CET on Thursday, November 12, 2026, 1.75 percent above the Xetra close of Wednesday, November 11, at EUR 250.35.

Healthcare portfolio sets context

Johnson & Johnson operates through its Innovative Medicine and MedTech segments. Innovative Medicine focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

MedTech includes products used in interventional solutions, orthopaedics, surgery and vision. The segment structure gives investors two main operating pillars to assess as regular European trading approaches.

US equities are tracked in the S&P 500 theme.

More news and analyses on Johnson & Johnson stock.

Disclaimer...
en | US4781601046 | JOHNSON & JOHNSON | boerse | 70495655 | bgmi